(RTTNews) - Retension Pharmaceuticals, Inc. (RTSN), a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, announced the pricing of its upsized initial public offering of 3.75 million shares at $12.00 per share. Retension Pharmaceuticals i
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.